Becton Dickinson (BDX) Stock Looks Cheap On Cash Flow Yet Fair On Earnings

Becton Dickinson stock has fallen around 18% over the past three years, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach currently points to meaningful upside relative to the market price, leaving investors to weigh that signal against a more mixed overall valuation score.

• The share price decline of about 18% over three years raises the question of whether the recent weakness has already accounted for the key risks, or if it reflects deeper concerns about long term value.
• Stronger recurring revenue from embedded healthcare workflows may support cash flow expectations, but the valuation still depends on how investors see execution risks around capital allocation and future growth projects.
• With a value score of 4 out of 6, Becton Dickinson screens as a mixed picture rather than a clear bargain or an obviously expensive stock.

The issue now is whether the current discount to the intrinsic value estimate for Becton Dickinson offers a reasonable margin of safety given the business outlook and risks.

Becton Dickinson delivered 15.3% returns over the last year. See how this stacks up to the rest of the Medical Equipment industry.

Is Becton Dickinson a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach values Becton Dickinson on the cash it is expected to generate for shareholders. The model uses latest twelve month free cash flow of about $3.0b and assumes cash flows continue growing from this base, which aligns with the company’s emphasis on recurring healthcare workflows. On this basis, the DCF points to an intrinsic value of about $204 per share.

That compares to the current share price, which implies a discount of around 21.5%, so the stock screens as undervalued on this cash flow view. Because Becton Dickinson recently reported solid Q2 growth and raised full year EPS guidance, the continued gap between price and intrinsic value suggests the market is still cautious about how future projects and capital decisions will translate into sustained cash generation.

Overall, the Discounted Cash Flow workup indicates Becton Dickinson stock currently appears undervalued relative to its projected cash flows.

Our Discounted Cash Flow (DCF) analysis suggests Becton Dickinson is undervalued by 21.5%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Becton Dickinson.

Is Becton Dickinson Fairly Priced on Earnings?

P/E is a useful lens for Becton Dickinson because earnings are a key focus for many investors watching the medical equipment sector. The stock currently trades on a P/E of about 26.8x, which sits slightly above the broader medical equipment industry average of roughly 26.1x but below the peer group average of around 30.9x.

The fair P/E ratio, which blends factors such as Becton Dickinson’s margins, scale and risk profile, sits near 28.1x. That is close to, but a little higher than, the current multiple. This suggests the shares are priced broadly in line with what this framework would indicate rather than pointing to a clear discount or premium.

On the P/E multiple, Becton Dickinson stock comes across as roughly fairly valued compared with both its own fundamentals and its industry benchmarks.

See what the numbers say about this price — find out in our valuation breakdown.

The Becton Dickinson Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Becton Dickinson pick up where this valuation puzzle leaves off by explaining which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price, and they sit on the company’s Community page. Each Narrative treats its implied fair value as a thesis about Becton Dickinson's business that you can revisit over time, rather than a one off snapshot.

The community is split on Becton Dickinson, with one camp seeing a reset opportunity while the other focuses on pressure points around utilization and pricing.

Bull case: 26% undervalued

"Recent and ongoing digitalization efforts, such as connectivity-enabled instruments, a nimble AI incubator, and software-driven diagnostic platforms, not only enhance customer retention but open the door to high-margin, recurring service revenue…"

Read the full Bull Case to see why Becton Dickinson could be undervalued

Bear case: 7% overvalued

"Heightened global healthcare cost-containment efforts and increasing preference for low-cost suppliers threaten Becton Dickinson's ability to maintain pricing power and margin stability, resulting in possible compression of both gross and net margins…"

Read the full Bear Case to see why Becton Dickinson could be overvalued

Do you think there's more to the story for Becton Dickinson? Head over to our Community to see what others are saying!

The Bottom Line

For Becton Dickinson, the Discounted Cash Flow (DCF) workup points to meaningful intrinsic value upside, while the P/E view suggests the stock is priced roughly in line with peers and its own fundamentals. The mixed overall valuation score reflects that split, with cash flow assumptions and capital intensity on one side, and market expectations and sector sentiment on the other. What really decides it from here is whether Becton Dickinson can turn its recurring healthcare workflows and future projects into the cash generation implied by the intrinsic value estimate, without eroding returns through execution or capital allocation missteps.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com